Buntanetap shows dose-dependent cognition gains; MDS-UPDRS improvements in PD Phase III

Annovis Bio, Inc.

Buntanetap at 20mg significantly improved MDS-UPDRS Part II, III, II+III, and Total in PD patients diagnosed >3 years.
In patients with mild dementia (MMSE 20-26), 20mg buntanetap showed significant cognitive improvement vs placebo.
PIGD subgroup also showed significant motor and non-motor improvements with buntanetap.
Safety profile consistent with prior AD data; no significant differences between early/advanced PD.
FDA feedback led to primary endpoint change; primary and secondary endpoints met in specified subgroups.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.